Abstract
Background:
Continuous glucose monitoring (CGM) patient systems have been shown to improve diabetes self-treatment when used consistently. The meaningful integration of this technology into everyday life, however, can vary greatly among CGM users and not all people with diabetes use CGM to its full potential. To address this issue, the study pursued 2 aims: first, to identify patient characteristics that underlie the acceptance of CGM in people with type 1 diabetes and, second, to examine the effects of different levels of experience with CGM use.
Methods:
Guided by a model based on the technology acceptance model (TAM), structural equation modeling (SEM) was employed to model the patient characteristics as predictors of CGM acceptance. In all, 111 participants (60.4% female, mean = 37.6 years, SD = 11.2) participated in a web-based survey; 40 were current CGM users, 18 were former users and 53 had no experience with CGM systems.
Results:
In general, participants evaluated CGM positively; however, the feeling of information overload represented a major barrier to the sustained use of CGM, while perceptions of usefulness and ease of use constituted incentives for using this technology. Moreover, patients without CGM experience imagined more information overload than current users reported. Current users showed more intention to use CGM than former users.
Conclusion:
This study highlights the importance of CGM user experience for the effective use of this technology.
Keywords
Continuous glucose monitoring (CGM) has been shown to be a powerful tool in type 1 diabetes self-management facilitating glycemic control, optimizing A1C, and avoiding hypoglycemia, when used consistently.1,2 However, CGM benefits can vary greatly among CGM users and not all patients use the technology to its full potential. 3 While there is clear evidence that users exhibiting high adherence and sustained CGM use benefit from it, a substantial number of people with diabetes do not succeed at integrating CGM into their diabetes self-management and, consequently, take less advantage of this technology.4,5 Physical, perceptual, cognitive, or behavioral aspects—also known as human factors 6 —may play a role in the effectiveness of CGM use. 3 Some human factors like expectations, perceived burden, and the ability to trust the technology have demonstrated before to be potential barriers to patients’ engagement with diabetes devices. 7
Ritholz and colleagues examined the differences between CGM users who showed a greater improvement in glycemic control (responders) and those who showed less improvement (nonresponders). 5 They differed, among other things, in the following facets: First, the attitudes of the patients’ family and social environment may either facilitate or impede effective CGM use, with supportive attitudes being more helpful. Second, nonresponders may have experienced information overload caused by the CGM’s real-time glucose readings. Furthermore, a perceived change in body image and a perceived increased visibility of diabetes while wearing CGM devices were found to be potential disadvantages.5,8
In a similar vein, another study showed that satisfaction with CGM was associated with a more frequent use of it and benefits of the CGM, like the availability of glucose trends/graphs and the ability to self-correct out-of-range glucose levels in real time, were found to influence CGM satisfaction. 8 Ease of use and the capacity to trust the information provided by CGM may play, in turn, a role in the perception of usefulness. 3 False alarms, for example, give the impression that CGM systems are sometimes unreliable.4,8
As with any other technology innovation, people clearly differ in how easily they accept and adopt CGM. Analogies may be drawn to studies that examined the adoption of information technology that found, for instance, a clear relationship between technology-related self-efficacy, also known as information technology expertise, 9 and perceived ease of use of technological systems.10,11 Based on this premise, we assume that technology-related self-efficacy should also play a role in conjunction with CGM use. Although technology-related self-efficacy is associated with age, with older people showing less self-efficacy in this field, 12 the effectiveness of CGM was found to be similar for all age groups when the technology was used intensely; however, older patients showed a considerably more frequent use of CGM system than younger patients such as children and adolescents. 1
We aimed to investigate these relationships with a focus on adult type 1 diabetics, pursuing 2 major goals: first, to identify possible motives that underlie the acceptance of CGM systems—defined here as the intention to use CGM to support one’s own diabetes treatment—and second, to compare characteristics between patient groups with different levels of CGM experience. For this purpose, we expanded a well-established model used in human factors research, the technology acceptance model (TAM; see Figure 1), 13 and derived and developed measures for psychosocial factors as identified in literature. The TAM has been widely used to investigate acceptance and use of technologies. 14 In this study, we predicted that the TAM expanded to include CGM-specific human factors (TAM-CGM) is suited to model CGM acceptance in people with type 1 diabetes. Furthermore, to investigate if these factors vary according to the level of experience with CGM, we hypothesized that patients without CGM experience, current users and former users differ in their perceptions of CGM.

Technology acceptance model (TAM). 13
Methods
Sample and Design
People with diabetes were approached in German-speaking diabetes self-help groups on Facebook as well as in other Internet forums about diabetes and invited to complete an online survey. Inclusion criteria were age ≥ 18 years and self-reported type 1 diabetes of at least 1-year disease duration. Patients who currently used or have previously used flash glucose monitoring (FGM) systems were excluded from participation. A total of 111 participants (60.4% female, age mean = 37.6 years, SD = 11.2) completed the survey (Table 1). Of the participants completing the survey, 40 used a CGM system at the time of data collection (group 1), 18 were former CGM users (group 2) and 53 had no CGM experience (group 3). The study protocol was approved by the local ethics committee. All participants gave their informed consent prior to completing the online survey.
Characteristics of Respondents.
Measurement of the Constructs
Since no validated measures were available for some of the variables in the CGM-TAM, novel scales were built based on relevant items of the CGM-Sat,
15
on the German translation of the Computer User Self-Efficacy scale
16
and on instruments that had previously been developed in TAM studies.13,17-19 The resulting questionnaire comprised 8 scales (see the appendix) besides age: Perceived Reliability was defined as the degree to which the patient confides in the CGM system and the glucose readings provided; Information Overload was defined as feelings of being overwhelmed by the novel kind of information continuously provided by CGM; Technology-Related Self-Efficacy describes confidence in one’s own skills in dealing with technology; Visibility of Body Change refers to the perception that one’s own body (image) changes while wearing a CGM system and that these undesired changes are visible for the patient and for others. The TAM scales were defined following Davis:
13
Usefulness describes the degree to which an individual believes that CGM improves their diabetes management; Ease of Use describes the extent to which an individual believes that using a CGM system does not require substantial additional physical or mental effort; Attitude refers to positive or negative feelings toward CGM; finally, Intention is defined as an individual’s subjective probability that they will use a CGM-System. Items were rated on a 6-point Likert-type scale ranging from
Data Analysis
After investigating the scales’ dimensionality with exploratory factor analysis (EFA) using the principal axis method, promax rotation and Kaiser criterion for each scale, we tested hypothesis 1 with structural equation modeling (SEM) using maximum likelihood (ML) estimation for the total sample. Relative χ2 value (χ2/
Results
All scales showed Kaiser–Meyer–Olkin values greater than .5, significant Bartlett test results (
Descriptive Statistics of the CGM-TAM Scales.
Model Fit
The original CGM-TAM did not reach the required thresholds of the quality criteria, for this reason we modified the model 7 times based on MI. MI offered relationships among items from different scales and among error terms, which suggests multicollinearity of the data. After modifications, the model showed to fit the data acceptably well, χ2/
Parameter Estimations
Figure 2 shows the final SEM with standardized parameter estimates of only the constructs. The path coefficients indicate that Information Overload had a strong negative influence on Ease of Use, β = –.943,

Parameter estimates of TAM-CGM with bootstrapped
All covariances in the CGM-TAM were added based on MI. Visibility of Body Change showed relationships that seemed to be implausible at first glance; however, the MI that suggested such covariances were very high and thus essential for the model fitness. The highest correlations were found between Information Overload and Visibility of Body Change (.677,
We performed bootstrap sampling with bias correction for the CI to estimate effects more reliably and to perform mediation analyses. The bootstrapping results could not confirm the ML-based
Standardized Total Effects in the SEM With Bootstrapped
Effects of CGM Experience
Before performing Kruskal–Wallis tests for the group comparisons, we used nonparametric Levene’s tests to verify the equality of variances in the samples.
25
The only variances between the groups which were not equal were of the scales Attitude (
Mean Ranks of the Groups and Pairwise Comparisons for Information Overload and Intention.
Significance level is .017 after Bonferroni correction.
Discussion
This online survey investigated the role of human factors in CGM usage as well as describing variation in these factors depending on the level of experience with CGM. The model developed for this analysis, CGM-TAM, was derived from the general TAM and adapted to the specifics of CGM use. It covered the factors Perceived Reliability, Information Overload, Technology-Related Self-Efficacy, Visibility of Body Change, Usefulness, Ease of Use, Attitude and Intention to use CGM, and exhibited a good fit to the data. In general, survey respondents perceived, irrespective of their level of experience, the advantages of CGM as high and the disadvantages as low. However, we found evidence that Information Overload, through its influence on Ease of Use, could represent a major barrier to the effective use of CGM. High Usefulness, Ease of Use and positive Attitude on the other hand constituted incentives for using the technology. Age, Perceived Reliability, Technology-Related Self-Efficacy, and Visibility of Body Change showed no effect. Moreover, patients without CGM experience imagined more Information Overload than current users reported. Not surprisingly, current users showed more Intention to use CGM than former users.
Usefulness showed a stronger effect than Ease of Use, which is similar to other studies.14,19 However, the relationships of both variables with Intention were according to bootstrapped
Limitations
Important limitations of this study are the strong violation of the normality assumption and the rather small sample size, which can be responsible for measurement errors.
26
Consequences of nonnormality concern an inflation of the χ2 value and the fact that the
Another limitation concerns the fact that to produce valid estimations, the sample must widely represent the intended population, in this case the type 1 diabetics. 29 Since the participants here tended to have a higher education level and were internet users, we cannot take this assumption for granted, so that we must expect even more bias in statistical estimations. 29 Furthermore, it would have been important to control for other relevant variables: for example, the different CGM models used by the participants of this survey.
Conclusions
The term “human factors” is used in the context of product use, safety and reliability and refers, in the field of diabetes technology, to individual characteristics and abilities that are related to design, operation and use of products for optimizing diabetes self-management. 7 The study showed one of these factors that may play an important role in consistent use of CGM, as the perception of Information Overload had a relevant negative effect on all key variables of TAM-CGM. Reduced complexity in the presentation of data may therefore facilitate CGM usability for some patients and thus improve user experience, possibly increasing adherence. The features of CGM should be clearly presented in marketing materials and, more importantly, the initial training for patients using a CGM system should focus on the complexity of the system.
FGM users were not included because of important differences between both systems: First, FGM does not need to be calibrated regularly, contrary to CGM; this could influence the perception of ease of use. Second, FGM is not able to trigger an alarm at risk of hypoglycemia; this can have consequences on the perception of usefulness, specially by users with hypoglycemia unawareness. Third, FGM users get more complex real-time information they need to interpret correctly, and this can lead to a different perception of ease of use and information overload. Hence, the results of this study may not be applicable to FGM users.
TAM-CGM is a model developed to assess CGM acceptance based on patient characteristics in an integrative manner. Based on the results of the present study, future research should focus on refining this model. Information Overload, Ease of Use and Usefulness appear to be promising key factors. Additional factors that could impact perceived information overload should also be considered: User characteristics, such as level of education, gender, or age, should be explored as they could act as powerful moderators. In this manner, it might be possible to identify what kind of patient could take better advantage of a reduced or increased complexity of data presentation: More concretely, it is possible that persons with a higher level of education might appreciate a more complex presentation of information or more available functions in a CGM-system. Following this approach, it would be possible to develop more appropriate CGM-models for specific target groups.
Footnotes
Appendix
Final TAM-CGM Scales and Items.
| Factor loadings (EFA) | |
|---|---|
| Perceived Reliability (Cronbach’s alpha = .88, explained variance = 65.5%) | |
| The device is very susceptible to interferences. a | .897 |
| CGM shows too many measurement errors. a | .825 |
| Overall, I think the system is reliable. | .794 |
| The device triggers false alarms too often. a | .710 |
| Information Overload (Cronbach’s alpha = .87, explained variance = 65.9%) | |
| Sometimes I do not know what to do with all the information provided by the CGM. | .884 |
| CGM provides too many readings. | .850 |
| It would be better if the CGM would provide less information. | .775 |
| CGM delivers too many information for me. | .728 |
| Technology-Related Self-Efficacy (Cronbach’s alpha = .84, explained variance = 64.88%) | |
| Generally, I think it is easy to learn how to use a new technology. | .854 |
| I feel me very confident in my abilities to make use of new technologies. | .782 |
| When I use a technological device, I do feel that I am in control. | .779 |
| Usefulness (Cronbach’s alpha = .85, explained variance = 56.2%) | |
| CGM makes it easier to keep blood glucose levels under control. | .889 |
| CGM improves diabetes self-management. | .787 |
| Ease of Use (Cronbach’s alpha = .86, explained variance = 67.6%) | |
| I think the system is ease to use. | .848 |
| I think it is difficult to adjust the system’s settings properly. a | .808 |
| Using the CGM is awkward. a | .811 |
| Attitude (Cronbach’s alpha = .85, explained variance = 68.6%) | |
| All in all, I can say: CGM to help with my diabetes disease is . . . | |
| Helpful. | .863 |
| Adversely. a | .863 |
| Visibility of Body Change (Cronbach’s alpha = .88, explained variance = 68.0%) | |
| CGM changes my body in a negative way. | .731 |
| CGM embarrasses me because I perceive myself as being different from the others. | .875 |
| I do not like to wear CGM because it arouses attention of other people. | .774 |
| The CGM embarrasses me, because I have to justify myself constantly. | .906 |
| Intention b (Cronbach’s alpha = .92, explained variance = 86.1%) | |
| Assuming I continue having a CGM, I intend to use it. (current users). | .928 |
| Assuming I obtain a CGM again, I intend to use it. (former users). | |
| Assuming I obtain a CGM, I intend to use it. (patients without experience). | |
| Given that I continue having access to a CGM system, I predict that I will use it. (current users) | .928 |
| Given that I have access to a CGM system again, I predict that I would use it. (former users) | |
| Given that I have access to a CGM system, I predict that I would use it. (patients without experience) | |
Translated from German. aThe score of these items were inverted in the data analysis. bThese items have been presented separately depending on experience with CGM and grouped accordingly for data analysis.
Abbreviations
CFI, comparative fit index; CGM, continuous glucose monitoring; CU, current users; EFA, exploratory factor analysis; FGM, flash glucose monitoring; FU, former users; IFI, incremental fit index; MI, modification indices; ML, maximum likelihood; PWE, patients without experience; RMSEA, root mean square error of approximation; SEM, structural equation modeling; TAM, technology acceptance model; TLI, Tucker–Lewis index.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
